Commercial over-the-counter cough syrups have been shown in various research
studies to be ineffective. So what can relieve a persistent cough due to cold in
children? Honey, according to a new study in the journal Pediatrics – but only
in children after their first birthday, as honey contains botulinum allergens
that may be dangerous for babies under one year of age.
In February 2010,
new Health Ministry regulations were issued limiting the use of cough syrups for
children. They can now be given to children if they are older than one year with
a doctor’s prescription only; these products used to be available over the
Now honey is a proven alternative.
The new randomized,
placebo-controlled study by Prof. Herman Avner Cohen at a Petah Tikva pediatric
community clinic and others compared the effects of a single dose of three honey
products (eucalyptus honey, citrus honey or labiatae honey) given at night to
silan (date extract) on nocturnal cough and difficulty sleeping associated with
childhood upper respiratory tract infections.
Some 300 children age one
to five years were given the honey or silan 30 minutes before bedtime. They were
tested for cough frequency, cough severity, bothersome nature of cough and child
and parent sleep quality, and the results were recorded by parents.
all three honey products and the placebo group, there was a significant
improvement from the night before treatment to the night of treatment. However,
the improvement was greater in the honey groups than the date extract
The honey products were higher than the silan for symptomatic
relief of the children’s nocturnal cough and sleep difficulty. Honey may be a
preferable treatment for cough and sleep difficulty associated with childhood
due to upper-respiratory infections, the researchers concluded.
JPOST VIDEOS THAT MIGHT INTEREST YOU:
Gene discovery offers hope for AML
Scientists at Yeshiva University’s Albert Einstein
College of Medicine in New York have made a discovery involving mice and humans
that could mean that people with acute myeloid leukemia (AML) – a rare and
usually fatal cancer – are a step closer to new treatment options. Their study
was published recently in the journal Cancer Cell.
“We have discovered
that a gene called HLX is expressed at abnormally high levels in leukemia stem
cells in a mouse model of AML,” said Prof. Ulrich Steidl, an expert in cell
biology and medicine at Einstein and senior author of the paper. Gene expression
is the process by which a gene synthesizes the molecule that it codes for; an
“overexpressed” gene makes its product in abnormally high
According to the US National Cancer Institute, AML is diagnosed
in one of every 254 people during their lifetime. Most die within a few years of
diagnosis. For the last several decades, there has been little improvement in
the survival rate for AML patients.
Steidl and colleagues found that
overexpression of the HLX gene in mice caused blood-forming stem cells to become
dysfunctional and develop into abnormal progenitors (biological ancestors) of
white blood cells that failed to differentiate into normal blood
Instead, those early, abnormal white cells formed duplicates of
themselves. The researchers then analyzed HLX expression data collected from 354
AML patients and found that 87 percent of them were overexpressing HLX compared
with HLX expression in healthy individuals.
And among patients expressing
HLX at high levels in an even larger cohort of 601 patients, they found that the
greater their degree of HLX expression, the worse their survival
When Dr. Steidl’s team used a laboratory technique to “knock
down” HLX expression in AML cells taken from a mouse model of AML and from AML
patients, proliferation of leukemia cells was greatly suppressed in both cases.
And when the researchers knocked down HLX expression in mouse AML cells and
human AML cells and then transplanted both types of cancer cells into healthy
mice, those mice lived significantly longer compared with mice that received
unaltered AML cells. These findings suggest that targeting elevated HLX
expression may be a promising, novel strategy for treating AML.
clearly a key factor in causing the over-production of white cells that occurs
in AML,” said Dr. Steidl. “Our research is still in its early stages, but we’re
looking toward developing drugs... so we can improve treatment for AML and
possibly other types of cancer.”
Einstein has filed a patent application
related to this research and seeking licensing partners.Fast-growing birthmarks
Strawberry-shaped birthmarks called infantile hemangiomas grow
rapidly in infants much earlier than previously thought, according to Mayo
Clinic and University of California, San Francisco researchers. Their study,
also published in Pediatrics, suggests that babies with complication- causing
hemangiomas should be immediately referred to dermatologists for further
Infantile hemangiomas are the most common tumor in infancy,
tend to appear in the first weeks of life and grow as a child
Potential complications include permanent disfigurement of the face
or functional compromise of vital organs.
“Our goal was to try to figure
out when this actual period of rapid growth happened,” said Dr. Megha Tollefson,
a pediatric dermatologist at the Mayo Clinic who conducted the study with Dr.
Ilona Frieden at the California university. “Then we could potentially intervene
if we had to.”
The researchers examined photos of 30 infants from birth
to three months, analyzing the color, thickness and distortion of anatomic
landmarks. Previously, physicians believed that the tumors grew during the first
five months of life, but researchers had not yet discovered when the most rapid
growth took place.
“By using a novel study design, we were able to
demonstrate that the period of most rapid hemangioma growth of superficial
hemangiomas occurs between 5.5 and 7.5 weeks of age,” Frieden said.
new findings suggest that infants with high-risk infantile hemangiomas should be
seen by a dermatologist as soon as possible, preferably by four weeks old. This
way, therapy such as drug treatment and laser removal can start as soon as
“Depending on where the hemangioma is located, it could
potentially have long-term impact,” Dr. Tollefson says. “We now have the
possibility of preventing a lot of that,” he concluded.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>